SHP-2 helps to mediate upstream activation of KRAS, especially the G12C mutant form that cycles more rapidly than most other mutants; however, it is also expressed in numerous immune cell types and inhibition of SHP-2 has been shown in preclinical tumor models to promote antitumor immunity and synergize with ICB (87). This evidence concerns the gene PTPN11 and neoplasm.